Medical Information

Doptelet, as a thrombopoietin receptor (TPO-R) agonist, has significant therapeutic effects on specific patients with thrombocytopenia. Its efficacy has been validated through indication coverage, onset time, and special population data, but individual differences and potential side effects should be noted.

1. Indicative validation effect

(1) Preoperative patients with chronic liver disease: can significantly increase platelet count to the surgical safety threshold and reduce bleeding risk.

(2) Chronic immune thrombocytopenia (ITP): It has a therapeutic response to both refractory ITP in adults and persistent ITP in children, improving symptoms of thrombocytopenia.

2. Pharmacodynamic data

(1) Effective time: The platelet count peak is reached on average 12 days after oral administration, and the bioavailability is dose-dependent.

(2) Continuous effect: Steady state blood drug concentration is reached on the 5th day after multiple administrations, with a half-life of about 27 hours to maintain the efficacy.

3. Special population effects

(1) Liver and kidney dysfunction: There is no significant change in pharmacokinetics in patients with mild to moderate damage, and the exposure level is reduced by 20% -30% in patients with severe liver function damage.

(2) Elderly patients: Existing data does not show any difference in efficacy compared to young adults, but individualized evaluation is needed.

4. Factors affecting therapeutic efficacy

(1) Drug interaction: There is no clinically significant effect when combined with multivalent cationic drugs, and the exposure level of specific drug combinations is stable.

(2) Food impact: A high-fat diet does not affect absorption, ensuring medication adherence.